RE:Almost 9 months into 2024 "We are almost 9 months into 2024 and what has been accomplished to bring the promised pipeline of opportunities to fruition."
It's all right in front of your nose and more. The merger is complete. The name and stock symbol change have just been made. CZO is now on NASDAQ - the largest stage for biotech in the world. The social media have been updated. The new website is "coming soon". Ronnie Miller notes the company is now "optimized" to bring "transformational" products to market. A "fulsome update" is to be released "shortly" after a detailed review according to the last news release. Diagnostic results appear imminent and will help define the potential financial resources for the go forward plan. The multi-dose portion of the avenanthramide trial is expected to be initiated in the next 30 days. PGX-YBG/fibrosis is being peer-reviewed by an influencial scientific journal. The company is presenting PGX before a conference of engineers on October 8. The Angiogesis Foundation wound healing research suggests CSCI can heal wounds in 1/2 the time and scarless. Other programs are also under review. Again, a fulsome update is expected shortly.